Dr. Roshal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000
Education & Training
University of WashingtonFellowship, Hematopathology, 2009 - 2010- University of WashingtonResidency, Pathology-Anatomic and Clinical, 2005 - 2008
University of Rochester School of Medicine and DentistryClass of 2005
Certifications & Licensure
NJ State Medical License 2021 - 2025
NY State Medical License 2010 - 2025
WA State Medical License 2007 - 2010- American Board of Pathology Pathology - Clinical
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- 1649 citationsLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaJae H. Park, Isabelle Riviere, Mithat Gonen, Xiuyan Wang, Brigitte Senechal
The New England Journal of Medicine. 2018-01-31 - 109 citationsClinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao
Blood Advances. 2021-03-09 - 29 citationsOutcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.Ana Alarcon Tomas, Joshua A Fein, Shalev Fried, Jessica R Flynn, Sean M Devlin
Leukemia. 2023-01-01
Journal Articles
- Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface MutationsMartin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
Abstracts/Posters
- Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute LeukemiaMikhail Roshal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...Mikhail Roshal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a Spike-in Clonal SequenceMikhail Roshal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
